Breast Oncology Program

乳腺肿瘤学项目

• 批准号: 10406945
• 负责人: Laura J Van't Veer
• 金额: $ 8.73万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-05 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10406945
• 关键词: Age; Biological; Biology; Breast Cancer Risk Factor; Breast Oncology; CDC2 gene; CDK2 gene; Cancer Center Support Grant; Cancer Etiology; Caring; Cessation of life; Clinical Trials; Development; Diagnostic; Direct Costs; Disease; ERBB2 gene; ERBB3 gene; Epithelial-Stromal Communication; Funding; Goals; Harm Reduction; Healthcare; Heterogeneity; Homeostasis; Image; Individual; Intervention; Knowledge; Malignant - descriptor; Malignant Neoplasms; Mammographic Density; Mammography; Metabolism; Mission; Molecular; Outcome; PIM1 gene; Pathway interactions; Patients; Peer Review; Physiological; Predisposition; Process; Publications; Radiation exposure; Research Personnel; Risk Estimate; San Francisco; Schools; Science; Therapeutic; Tissues; Toxic effect; Woman; Work; base; checkpoint modulation; cost; disorder risk; drug development; high risk; immune checkpoint; improved; improved outcome; individualized medicine; innovation; malignant breast neoplasm; mammography registry; new therapeutic target; oncology program; overtreatment; personalized diagnostics; personalized screening; prevent; programs; randomized trial; routine screening; screening; success; tool; treatment response; trial design; triple-negative invasive breast carcinoma

Breast Oncology Program: Summary The mission of the Breast Oncology (BR) Program is to develop innovative approaches to describe the molecular and cellular networks underlying breast cancer susceptibility, heterogeneity, diversity, and disparities with the aim of improving outcomes for healthy women and women with breast cancer. The BR Program's work aims to reduce overdiagnosis and overtreatment through individualizing screening and treatment, and derive better outcomes at lower cost. The BR Program achieves its goals through four themes: Theme 1: Improving the Understanding of Breast Cancer Etiology in the Context of the Microenvironment Theme 2: Personalizing Screening and Diagnostics to Increase Health Care Value Theme 3: Identifying New Therapeutic Targets for High-risk Disease Theme 4: Augmenting Efficiency of Drug Development through Innovative Trial Design BR Program: Key Metrics Membership (14 departments, 3 schools) 33 Full 18 Associate 15 Cancer-relevant Funding (direct costs as of $14,454,243 05/31/2017) NCI $5,307,970 37% Peer-reviewed $4,630,302 32% Non-peer-reviewed $4,515,971 31% Cancer-relevant Publications (1/2012-7/2017) 636 Inter-programmatic 141 22% Intra-Programmatic 175 28% High-Impact 190 30% Accruals to Clinical Trials (2016) 5293 58 Therapeutic 140 31 Other Interventional 9 4 Non-interventional 5144 22

乳腺肿瘤学项目：总结 乳腺肿瘤学（BR）项目的使命是开发创新方法来描述 乳腺癌易感性、异质性、多样性和差异性的分子和细胞网络 目的是改善健康妇女和乳腺癌妇女的预后。BR计划 工作旨在通过个性化筛查和治疗减少过度诊断和过度治疗， 以更低的成本获得更好的结果。BR计划通过四个主题实现其目标： 主题1：在微环境背景下提高对乳腺癌病因学的理解 主题2：个性化筛查和诊断以提高医疗保健价值 主题3：确定高危疾病的新治疗靶点 主题4：通过创新试验设计提高药物开发效率 BR计划：关键步骤 成员（14个部门，3所学校）33 整整18 助理15 与癌症有关的供资（截至2009年的直接费用） 14 454 243美元 2017年05月31日） NCI 5，307，970美元37% 同行评审$4，630，302 32% 非同行评审4，515，971美元31% 癌症相关出版物（1/2012-7/2017）636 跨项目141 22% 方案内 高影响力190 30% 临床试验应计费用（2016年）5293 58 治疗140 31 其他干预措施9 4 非干预性